At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Paclitaxeldrug
Likely dose
Paclitaxel 100 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
In Brief
A Phase 2 clinical trial evaluating Paclitaxel for Head and Neck Cancer. Completed, enrolled 11 participants across 9 sites.
Detailed Summary
The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator, and to evaluate the frequency and the severity of observed adverse reactions in treated subjects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
Primary CompletionNov 2008
First PostedSep 2009
TodayJul 2026
First PostedSep 4, 2009
Enrollment StartAug 4, 2006
Primary CompletionNov 26, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.8 years ago
Interventions
Paclitaxeldrug
Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent